Center for Chronic Lymphocytic Leukemia

Patients have the opportunity to participate in trials for new therapies for all phases of Chronic Lymphocytic Leukemia (CLL), including advanced CLL. These trials include:

• Agents that prime CLL cells to die when they are hit with chemotherapy
• Drugs that block key drivers of CLL cell growth, including kinase inhibitors

Learn more about clinical trials for CLL patients.

Translational science, which quickly moves laboratory findings into clinical practice, is also a key focus of the Center for Chronic Lymphocytic Leukemia. This includes:

• Providing CLL samples to a large network of collaborators who are working to better understand how CLL develops and how we can best target it with the goal of finding a cure
• Examining genetic material of a variety of CLLs in order to identify genetic changes that cause CLL

Genetic Study of Familial Chronic Lymphocytic Lymphoma

Dana-Farber is currently enrolling participants for a Genetic Study of Familial Chronic Lymphocytic Lymphoma. This study, led by Jennifer R. Brown, MD, PhD, seeks to identify the genes that cause the disease, in order to develop methods of prevention and diagnosis counseling. To be eligible, participants must have at least two first-degree relatives (e.g., parent, sibling, or child) who have a lymphoma or lymphoproliferative disorder. For more information, including detailed eligibility guidelines and participation requirements, contact lead investigator Jennifer R Brown, MD, PhD or study coordinator Alexander Vartanov.

Learn more about the Harvard Study of Genetic Factors that Lead to Lymphoma